At the EHA annual meeting in Amsterdam, Editorial Board member Robin Foà joins us to discuss the latest initiatives surrounding CAR-T cells and their use in the treatment of haematological malignancies.
1. What are the major challenges to incorporating CAR-T cells into clinical practice? (0:06)
2. Where are CAR-T cells likely to fit into the treatment paradigm for haematological malignancies? (1:46)
3. Why is it important to quantify minimal residual disease in haematological malignancies? (2:57)
4. How have new molecular technologies impacted on the evaluation of minimal residual disease? (4:30)
5. How will this breakthrough impact future clinical practice? (5:48)
Professor Robin Foà has no conflicts of interest in relation to this video.
Filmed at the European Hematology Association (EHA) 24th congress 2019, Amsterdam, Netherlands.
touchONCOLOGY.com is an independent information resource supporting physicians, clinicians and leading industry professionals in continuously developing their knowledge, effectiveness and productivity, via free-to-access content in multimedia formats.
Share this Video
Related Videos In Immunotherapy
Leisha A Emens, ESMO 2020 – Overall Survival Analysis from IMpassion 130 in Triple-negative Breast Cancer
Prof. Leisha A Emens joins touchONCOLOGY to discuss the final overall survival analysis of the phase III IMpassion 130 study investigating atezolizumab plus nab-paclitaxel versus placebo plus nab-paclitaxel in previously untreated locally advanced or metastatic triple-negative breast cancer. Prof. Emens explores what we can learn from these findings, as well as the failure of IMpassion […]
IBRAHIM EL HOUSSIENY, EHA 2019 – CAR-T cells and manufacturing (Part 2)
Ibrahim El Houssieny joins us at the EHA annual meeting in Amsterdam to discuss the most important recent therapeutic advances and manufacturing of CAR-T cells. This is part 2 of his interview, part one can be viewed here. Questions 1. How can we mitigate the toxicities associated with CAR-T cell therapy? (0:05) 2. What is […]
IBRAHIM EL HOUSSIENY, EHA 2019 – CAR-T cells and manufacturing (Part 1)
Ibrahim El Houssieny joins us at the EHA annual meeting in Amsterdam to discuss the most important recent therapeutic advances and manufacturing of CAR-T cells. This is part 1 of his interview, part two can be viewed here. Questions 1. What have been the most exciting recent developments in CAR-T cell therapy? (0:05) 2. Which […]
Journal articles and more to your inbox
Get the latest clinical insights from touchONCOLOGYSign me up!